|
1
|
Charles CH, Yoon JK, Simske JS and Lau LF:
Genomic structure, cDNA sequence, and expression of gly96, a growth
factor-inducible immediate-early gene encoding a short-lived
glycosylated protein. Oncogene. 8:797–801. 1993.PubMed/NCBI
|
|
2
|
Kondratyev AD, Chung KN and Jung MO:
Identification and characterization of a radiation-inducible
glycosylated human early-response gene. Cancer Res. 56:1498–1502.
1996.PubMed/NCBI
|
|
3
|
Arlt A and Schäfer H: Role of the
immediate early response 3 (IER3) gene in cellular stress response,
inflammation and tumorigenesis. Eur J Cell Biol. 90:545–552. 2011.
View Article : Google Scholar
|
|
4
|
Wu MX: Roles of the stress-induced gene
IEX-1 in regulation of cell death and oncogenesis. Apoptosis.
8:11–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasada T, Azuma K, Hirai T, Hashida H,
Kanai M, Yanagawa T and Takabayashi A: Prognostic significance of
the immediate early response gene X-1 (IEX-1) expression in
pancreatic cancer. Ann Surg Oncol. 15:609–617. 2008. View Article : Google Scholar
|
|
6
|
Han L, Geng L, Liu X, Shi H, He W and Wu
MX: Clinical significance of IEX-1 expression in ovarian carcinoma.
Ultrastruct Pathol. 35:260–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang C, Trent S, Ionescu-Tiba V, Lan L,
Shioda T, Sgroi D and Schmidt EV: Identification of cyclin D1- and
estrogen-regulated genes contributing to breast carcinogenesis and
progression. Cancer Res. 66:11649–11658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steensma DP, Neiger JD, Porcher JC, Keats
JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila
R, Kumar R, et al: Rearrangements and amplification of IER3 (IEX-1)
represent a novel and recurrent molecular abnormality in
myelodysplastic syndromes. Cancer Res. 69:7518–7523. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janssens V and Goris J: Protein
phosphatase 2A: A highly regulated family of serine/threonine
phosphatases implicated in cell growth and signalling. Biochem J.
353:417–439. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee TY, Lai TY, Lin SC, Wu CW, Ni IF, Yang
YS, Hung LY, Law BK and Chiang CW: The B56γ3 regulatory subunit of
protein phosphatase 2A (PP2A) regulates S phase-specific nuclear
accumulation of PP2A and the G1 to S transition. J Biol Chem.
285:21567–21580. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eichhorn PJ, Creyghton MP and Bernards R:
Protein phosphatase 2A regulatory subunits and cancer. Biochim
Biophys Acta. 1795:1–15. 2009.
|
|
12
|
Westermarck J and Hahn WC: Multiple
pathways regulated by the tumor suppressor PP2A in transformation.
Trends Mol Med. 14:152–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Letourneux C, Rocher G and Porteu F:
B56-containing PP2A dephosphorylate ERK and their activity is
controlled by the early gene IEX-1 and ERK. EMBO J. 25:727–738.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia J, Ye Y, Arranz V, Letourneux C,
Pezeron G and Porteu F: IEX-1: A new ERK substrate involved in both
ERK survival activity and ERK activation. EMBO J. 21:5151–5163.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mebratu Y and Tesfaigzi Y: How ERK1/2
activation controls cell proliferation and cell death: Is
subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wortzel I and Seger R: The ERK cascade:
Distinct functions within various subcellular organelles. Genes
Cancer. 2:195–209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawahara E, Maenaka S, Shimada E,
Nishimura Y and Sakurai H: Dynamic regulation of extracellular
signal-regulated kinase (ERK) by protein phosphatase 2A regulatory
subunit B56γ1 in nuclei induces cell migration. PLoS One.
8:e637292013. View Article : Google Scholar
|
|
18
|
Traverse S, Gomez N, Paterson H, Marshall
C and Cohen P: Sustained activation of the mitogen-activated
protein (MAP) kinase cascade may be required for differentiation of
PC12 cells. Comparison of the effects of nerve growth factor and
epidermal growth factor. Biochem J. 288:351–355. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marshall CJ: Specificity of receptor
tyrosine kinase signaling: Transient versus sustained extracellular
signal-regulated kinase activation. Cell. 80:179–185. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nobumori Y, Shouse GP, Wu Y, Lee KJ, Shen
B and Liu X: Characterization of B56γ tumor-associated mutations
reveals mechanisms for B56γ-PP2A tumor suppressor activity. Mol
Cancer Res. 11:995–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tepeli E, Muslumanoglu MH, Uludag A,
Buyukpinarbasili N, Ozdemir M, Oznur M, Aslan H and Artan S:
Detection of deletions and/or amplifications of genes related with
lung cancer by multiplex ligation-dependent probe amplification
(MLPA) technique. Cancer Biol Ther. 8:2160–2165. 2009. View Article : Google Scholar
|
|
22
|
Bando T, Kato Y, Ihara Y, Yamagishi F,
Tsukada K and Isobe M: Loss of heterozygosity of 14q32 in
colorectal carcinoma. Cancer Genet Cytogenet. 111:161–165. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ihara Y, Kato Y, Bando T, Yamagishi F,
Minamimura T, Sakamoto T, Tsukada K and Isobe M: Allelic imbalance
of 14q32 in esophageal carcinoma. Cancer Genet Cytogenet.
135:177–181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ito A, Kataoka TR, Watanabe M, Nishiyama
K, Mazaki Y, Sabe H, Kitamura Y and Nojima H: A truncated isoform
of the PP2A B56 subunit promotes cell motility through paxillin
phosphorylation. EMBO J. 19:562–571. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li
B, Lu Y, Geng S, Du X and Li Y: Expression and distribution of
PPP2R5C gene in leukemia. J Hematol Oncol. 4:212011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koudelakova V, Kneblova M, Trojanec R,
Drabek J and Hajduch M: Non-small cell lung cancer - genetic
predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
157:125–136. 2013.PubMed/NCBI
|
|
28
|
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK,
Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, et al: The
transcriptional landscape and mutational profile of lung
adenocarcinoma. Genome Res. 22:2109–2119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hiramatsu M, Ninomiya H, Inamura K, Nomura
K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura
M, et al: Activation status of receptor tyrosine kinase downstream
pathways in primary lung adenocarcinoma with reference of KRAS and
EGFR mutations. Lung Cancer. 70:94–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stella GM, Scabini R, Inghilleri S, Cemmi
F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, Ferrari S, et
al: EGFR and KRAS mutational profiling in fresh non-small cell lung
cancer (NSCLC) cells. J Cancer Res Clin Oncol. 139:1327–1335. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chung BM, Dimri M, George M, Reddi AL,
Chen G, Band V and Band H: The role of cooperativity with Src in
oncogenic transformation mediated by non-small cell lung
cancer-associated EGF receptor mutants. Oncogene. 28:1821–1832.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinehart J, Adjei AA, Lorusso PM,
Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury
P, Kaldjian EP, et al: Multicenter phase II study of the oral MEK
inhibitor, CI-1040, in patients with advanced non-small-cell lung,
breast, colon, and pancreatic cancer. J Clin Oncol. 22:4456–4462.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Erman M, Grunenwald D, Penault-Llorca F,
Grenier J, Besse B, Validire P, Morat L, Girard P, Le Chevalier T,
Sabatier L, et al: Epidermal growth factor receptor, HER-2/neu and
related pathways in lung adenocarcinomas with bronchioloalveolar
features. Lung Cancer. 47:315–323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu MX, Ustyugova IV, Han L and Akilov OE:
Immediate early response gene X-1, a potential prognostic biomarker
in cancers. Expert Opin Ther Targets. 17:593–606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garcia MN, Grasso D, Lopez-Millan MB,
Hamidi T, Loncle C, Tomasini R, Lomberk G, Porteu F, Urrutia R and
Iovanna JL: IER3 supports KRASG12D-dependent pancreatic cancer
development by sustaining ERK1/2 phosphorylation. J Clin Invest.
124:4709–4722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ria R, Todoerti K, Berardi S, Coluccia AM,
De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A,
Petrucci MT, et al: Gene expression profiling of bone marrow
endothelial cells in patients with multiple myeloma. Clin Cancer
Res. 15:5369–5378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Y: Serine/threonine phosphatases:
Mechanism through structure. Cell. 139:468–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Janssens V, Goris J and Van Hoof C: PP2A:
The expected tumor suppressor. Curr Opin Genet Dev. 15:34–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Abujiang P, Mori TJ, Takahashi T, Tanaka
F, Kasyu I, Hitomi S and Hiai H: Loss of heterozygosity (LOH) at
17q and 14q in human lung cancers. Oncogene. 17:3029–3033. 1998.
View Article : Google Scholar
|
|
41
|
Kwong FM, Wong PS and Lung ML: Genetic
alterations detected on chromosomes 13 and 14 in Chinese non-small
cell lung carcinomas. Cancer Lett. 192:189–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Al-Mulla F, AlFadhli S, Al-Hakim AH, Going
JJ and Bitar MS: Metastatic recurrence of early-stage colorectal
cancer is linked to loss of heterozygosity on chromosomes 4 and
14q. J Clin Pathol. 59:624–630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hoshi M, Shiwaku HO, Hayashi Y, Kaneko Y
and Horii A: Deletion mapping of 14q32 in human neuroblastoma
defines an 1,100-kb region of common allelic loss. Med Pediatr
Oncol. 35:522–525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dai YC, Ho CL, Tsai YC, Hsu YH, Chang YC,
Liu HS, Chen HH and Chow NH: Allelic loss of 14q32 in the
pathogenesis of gastrointestinal and ampullary malignancies:
Mapping of the target region to a 17 cM interval. J Cancer Res Clin
Oncol. 131:94–100. 2005. View Article : Google Scholar
|
|
45
|
Pécuchet N, Popova T, Manié E, Lucchesi C,
Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M,
Sigal-Zafrani B, Sastre-Garau X, et al: Loss of heterozygosity at
13q13 and 14q32 predicts BRCA2 inactivation in luminal breast
carcinomas. Int J Cancer. 133:2834–2842. 2013.PubMed/NCBI
|
|
46
|
Sekido Y, Fong KM and Minna JD: Progress
in understanding the molecular pathogenesis of human lung cancer.
Biochim Biophys Acta. 1378:F21–F59. 1998.PubMed/NCBI
|
|
47
|
Wang SS, Esplin ED, Li JL, Huang L, Gazdar
A, Minna J and Evans GA: Alterations of the PPP2R1B gene in human
lung and colon cancer. Science. 282:284–287. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Carmen Figueroa-Aldariz M,
Castañeda-Patlán MC, Santoyo-Ramos P, Zentella A and Robles-Flores
M: Protein phosphatase 2A is essential to maintain active Wnt
signaling and its Aβ tumor suppressor subunit is not expressed in
colon cancer cells. Mol Carcinog. 54:1430–1441. 2015. View Article : Google Scholar
|
|
49
|
Rasio D, Negrini M, Manenti G, Dragani TA
and Croce CM: Loss of heterozygosity at chromosome 11q in lung
adenocarcinoma: Identification of three independent regions. Cancer
Res. 55:3988–3991. 1995.PubMed/NCBI
|
